

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 April 2022 (07.04.2022)



(10) International Publication Number
WO 2022/069557 A2

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 14/725 (2006.01)
A61P 35/00 (2006.01) C07K 16/28 (2006.01)
C07K 7/02 (2006.01) C12N 5/0783 (2010.01)
C07K 7/06 (2006.01)

(21) International Application Number:

PCT/EP2021/076821

(22) International Filing Date:

29 September 2021 (29.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10 2020 125 457.1
29 September 2020 (29.09.2020) DE
63/084,963 29 September 2020 (29.09.2020) US

(71) Applicant: IMMATICS BIOTECHNOLOGIES GMBH
[DE/DE]; Paul-Ehrlich-Str. 15, 72076 Tübingen (DE).

(72) Inventors: HUKELMANN, Jens; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). SCHUSTER, Heiko; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). HANNEN, Ricarda; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). SCHRÄDER, Christoph; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). FRITSCHKE, Jens; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). HOFFGAARD, Franziska; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). KOWALEWSKI, Daniel; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE). SCHOOR, Oliver; c/o Immatics Biotechnologies GmbH, Paul-Ehrlich-Straße 15, 72076 Tübingen (DE).

(74) Agent: MICHALSKI HÜTTERMANN & PARTNER
PATENTANWÄLTE MBB et al.; Speditionstraße 21,
D-40221 Düsseldorf (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS

(57) Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

WO 2022/069557 A2